Processing

Please wait...

Settings

Settings

Goto Application

1. WO2017189826 - USE OF CELL-PERMEABLE PEPTIDES AND NON-PEPTIDE CARRIERS CONJUGATED WITH NEMO BINDING DOMAIN CARGO SEQUENCE FOR THE TREATMENT OF DRY EYE DISEASE AND UVEITIS

Publication Number WO/2017/189826
Publication Date 02.11.2017
International Application No. PCT/US2017/029801
International Filing Date 27.04.2017
IPC
A61K 47/50 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
A61K 47/56 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
56the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
A61K 47/65 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
C12N 5/10 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
CPC
A61K 47/64
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C07K 14/435
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
Applicants
  • PORTAGE PHARMACEUTICALS LTD. [CA]/[CA]
  • LITTMAN, Bruce, H. [US]/[US] (US)
Inventors
  • LITTMAN, Bruce, H.
Agents
  • FOURNIER, David, B.
  • ARNETT, Stephen, E.
  • BALTAZAR, David, J.
  • BAILEY, Robert, A.
  • AI, Bing
Priority Data
62/329,54029.04.2016US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) USE OF CELL-PERMEABLE PEPTIDES AND NON-PEPTIDE CARRIERS CONJUGATED WITH NEMO BINDING DOMAIN CARGO SEQUENCE FOR THE TREATMENT OF DRY EYE DISEASE AND UVEITIS
(FR) UTILISATION DE PEPTIDES PERMÉABLES AUX CELLULES ET DE VÉHICULES NON PEPTIDIQUES LIÉS À LA SÉQUENCE CARGO DU DOMAINE DE LIAISON NEMO POUR LE TRAITEMENT DU SYNDROME DE L'ŒIL SEC ET DE L'UVÉITE
Abstract
(EN)
Provided herein are compositions and methods for treating dry eye disease and uveitis through administration of cell permeable peptide conjugates linked with NFKB essential modulator (NEMO) binding domain. These peptides facilitate entry into tissues, cells and the nucleus of cells thus allowing the NEMO binding domain to reach its site of action for therapeutic purposes.
(FR)
L'invention concerne des compositions et des méthodes de traitement du syndrome de l'œil sec et de l'uvéite par administration de conjugués peptidiques perméables aux cellules liés au domaine de liaison du modulateur essentiel de NF-κB (NEMO). Ces peptides facilitent l'entrée dans les tissus, les cellules et le noyau des cellules, ce qui permet ainsi au domaine de liaison NEMO d'atteindre son site d'action à des fins thérapeutiques.
Latest bibliographic data on file with the International Bureau